Alkermes at buy by Merrill

Merrill Lynch analyst Hari Sambasivam rated Alkermes Inc. at s buy after the company's marketing partner, Cephalon, recorded no Vivitrol sales in its second quarter since it was only on the market for part of June. IMS, however, did report sales of $1.2 million for June, according to the analyst. More details on the Vivitrol launch are expected during Alkermes' earnings call in the Aug. 7 week. Shares of the Cambridge, Mass.-based pharmaceutical company were down 32 cents, or 1.85%, at $17.00 on volume of 881,837 shares versus the three-month running average of 1.119,710 shares. (Nasdaq: ALKS)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.